Pediatric craniopharyngioma: when hypoglycemia reveals a brain tumor. Illustrative case

Oualid M Hmamouche1, Marouane Hammoud1, Faycal Lakhdar1

  • 1Department of Neurosurgery, Hassan II University Hospital, Fez, Morocco.

Insights

Craniopharyngioma can rarely cause severe hypoglycemia and coma in children. Prompt endocrine evaluation and imaging are vital for early diagnosis and effective management of this rare presentation.

Area of Science:

  • Pediatric Endocrinology
  • Pediatric Neurosurgery
  • Oncology

Background:

  • Craniopharyngiomas (CPs) typically present with symptoms like intracranial hypertension, visual disturbances, or growth failure.
  • Hypoglycemia as an initial symptom of craniopharyngioma is exceptionally rare, indicating hypothalamic-pituitary dysfunction.

Purpose of the Study:

  • To highlight the rare presentation of craniopharyngioma with severe hypoglycemia.
  • To emphasize the importance of prompt endocrine evaluation and imaging for unexplained pediatric hypoglycemia.

Main Methods:

  • A case report of a 4-year-old girl presenting with coma and severe hypoglycemia.
  • Diagnostic workup included endocrine testing and brain MRI.
  • Sellar-suprasellar mass (craniopharyngioma) was surgically resected.

Main Results:

  • The patient experienced recurrent hypoglycemia, central adrenal insufficiency, and hypothyroidism.
  • Brain MRI revealed a cystic sellar-suprasellar mass.
  • Histopathology confirmed adamantinomatous craniopharyngioma; postoperative hypoglycemia resolved with hormone replacement.

Conclusions:

  • Craniopharyngioma can exceptionally present with severe recurrent hypoglycemia and coma in children.
  • Prompt endocrine evaluation and sellar imaging are crucial for unexplained pediatric hypoglycemia.
  • Multidisciplinary management involving neurosurgery and endocrinology is key for favorable outcomes.
Abstract

Related Concept Videos

Hypoglycemia and Glucagon01:15

Hypoglycemia and Glucagon

Without prolonged fasting, healthy individuals maintain blood glucose levels above 3.5 mM due to a well-adapted neuroendocrine counterregulatory system that effectively prevents acute hypoglycemia, a potentially life-threatening condition. The primary clinical scenarios for hypoglycemia encompass diabetes treatment, inappropriate production of endogenous insulin or insulin-like substances by tumors, and the use of glucose-lowering agents in non-diabetic individuals. Notably, hypoglycemia in the...
983
Pharmacokinetics in Pediatric Patients: Drug Excretion01:26

Pharmacokinetics in Pediatric Patients: Drug Excretion

In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
262
Pharmacokinetics in Pediatric Patients: Drug Distribution01:17

Pharmacokinetics in Pediatric Patients: Drug Distribution

Drug distribution in the pediatric population exhibits unique challenges and considerations due to the physiological differences between children, particularly neonates and infants, and adults. A crucial aspect of pediatric pharmacology is understanding how these differences impact the pharmacokinetics of various drugs, necessitating age-specific dosing strategies to ensure efficacy and safety.Neonates and infants have a higher total body water content, ~75%–90% of their body weight,...
304
Pharmacokinetics in Pediatric Patients: Drug Metabolism01:24

Pharmacokinetics in Pediatric Patients: Drug Metabolism

In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses...
226
Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption01:23

Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption

Understanding the physiological differences in the pediatric population is crucial for effective pharmacotherapy. Neonates, infants, and children exhibit significant variations in gastric pH, gastric emptying time, intestinal transit time, and biliary function. These variations profoundly affect oral drug absorption, necessitating a nuanced approach to pediatric dosing.Neonates present with a unique physiological profile, having a gastric pH greater than 4 and faster and more irregular gastric...
296